Table 3.
Hazard ratios estimating the relative risk of death from COVID-19 associated with baseline hormone concentration.§
Model | Q1 (lowest) | Q2 | Q3 | Q4 | Q5 (highest) | P-value (term) |
---|---|---|---|---|---|---|
Total testosterone (nmol/L) | ||||||
Events per quintile | 112 | 94 | 86 | 68 | 78 | |
n per quintile | 31 992 | 32 169 | 32 081 | 31 933 | 31 789 | |
Model 1# | 1.37 (1.07–1.75) | 1.08 (0.85–1.41) | 0.93 (0.78–1.14) | 0.87 (0.79–0.98) | ref. | <0.001 |
Model 2## | 0.84 (0.65–1.12) | 0.82 (0.63–1.10) | 0.80 (0.66–1.00) | 0.82 (0.75–0.93) | ref. | 0.008 |
SHBG (nmol/L) | ||||||
Events per quintile | 76 | 79 | 87 | 86 | 110 | |
n per quintile | 31 980 | 32 121 | 32 054 | 31 982 | 31 827 | |
Model 1# | 1.61 (1.23–2.07) | 1.27 (0.98–1.64) | 1.06 (0.86–1.30) | 0.93 (0.85–1.02) | ref. | <0.001 |
Model 2## | 1.01 (0.77–1.34) | 0.94 (0.72–1.24) | 0.89 (0.71–1.11) | 0.87 (0.79–0.97) | ref. | 0.008 |
cFT (pmol/L) | ||||||
Events per quintile | 137 | 110 | 76 | 66 | 49 | |
n per quintile | 31 738 | 32 051 | 32 126 | 32 073 | 31 976 | |
Model 1# | 1.13 (0.86–1.5) | 0.93 (0.7–1.24) | 0.89 (0.73–1.12) | 0.91 (0.84–1.09) | ref. | 0.004 |
Model 2## | 0.86 (0.65–1.17) | 0.81 (0.61–1.10) | 0.83 (0.68–1.07) | 0.89 (0.82–1.06) | ref. | 0.248 |
§Hazard ratios calculated for the medians of testosterone within each sample quintile (Q1–Q5), relative to the median for Q5. Quintile boundaries: testosterone: (nmol/L) Q1/2 9.0, Q2/3 10.8, Q3/4 12.5, and Q4/5 14.8 or (ng/dL) Q1/2 259, Q2/3 311, Q3/4 360, and Q4/5 427; SHBG: (nmol/L) Q1/2 25.8, Q2/3 33.1, Q3/4 40.5, and Q4/5 50.8; cFT: (pmol/L) Q1/2 171, Q2/3 201, Q3/4 230, and Q4/5 268. #Model 1 included terms for testosterone and age and region, with time modelled as a 3-level stratification factor plus an interaction of region with time (see Methods). ##Model 2 included model 1 terms + ethnicity (White vs not White), living with partner, educational attainment, alcohol consumption, smoking status, diet (red meat: high vs low vs none), physical activity, BMI, waist circumference, cholesterol, time blood sample collected, blood type, Townsend Index quintile, diabetes, hypertension, angina, atrial fibrillation, COPD, renal impairment, liver disease, thyroid disease, and use of lipid medications (a proxy for hyperlipidemia), glucocorticoids, opioids, and anticonvulsants, with the number of medications included as a proxy for overall comorbidity status. Continuous variables are modelled using restricted cubic splines (see Methods).